Table 4.
Percent distribution of adverse effects of AL among participants in each age group and sex, Bahir Dar district, March to July 2012
| Adverse effects | Sex | Age group in years (%) | Total (130) | ||||
|---|---|---|---|---|---|---|---|
| 5–14 (42) | 15–24 (29) | 25–34 (29) | 35–44 (16) | 45+ (14) | |||
| Weakness | M | 24 | 10 | 16 | 6 | 0 | 15.9 |
| F | 8 | 14 | 4 | 4 | 0 | ||
| Headache | M | 24 | 16 | 20 | 10 | 0 | 15.9 |
| F | 12 | 9 | 0 | 0 | 0 | ||
| Mouth rash | M | 10.4 | 8 | 15 | 17.4 | 0 | 14.7 |
| F | 13.0 | 21.7 | 0 | 4.4 | 0 | ||
| Cough | M | 7.2 | 12.7 | 16. 7 | 0 | 0 | 11.5 |
| F | 13.1 | 16.7 | 0 | 0 | 0 | ||
| Abdominal pain | M | 21.4 | 21.4 | 21.4 | 0 | 7.14 | 8.9 |
| F | 0 | 21.4 | 7.1 | 0 | 0 | ||
| Sore throat | M | 11.3 | 7.1 | 0 | 5.2 | 0 | 8.9 |
| F | 21.4 | 15.7 | 0 | 7.1 | 0 | ||
| Tongue Inflammation | M | 6.1 | 9.2 | 0 | 9.1 | 0 | 7.01 |
| F | 7.3 | 16.4 | 0 | 0 | 0 | ||
| Joint pain | M | 9.8 | 0 | 0 | 10 | 0 | 2.6 |
| F | 0 | 6 | 0 | 0 | 0 | ||
| Loss of appetite | M | 0 | 0 | 0 | 8 | 0 | 1.3 |
| F | 0 | 0 | 0 | 0 | 0 | ||
All adverse effects seen in the study were registered under FDA as the usual type side effects. In the study the most frequents were weakness and headache followed by mouth rash. Whereas, loss of appetite and joint pains were the least among others